Vol. 3 No. 8 (2023)
Reimbursement Reviews

Upadacitinib (Rinvoq)

decorative image of the issue cover

Published August 28, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses upadacitinib (Rinvoq), 15 mg and 30 mg extended-release tablets, oral.
  • Indication: For the treatment of adults with active ankylosing spondylitis who have had an inadequate response to a biologic disease-modifying antirheumatic drug or when use of those therapies is inadvisable; may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs.